Gyre Therapeutics, Inc. GYRE Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s deferred revenue?
- Gyre Therapeutics, Inc. (GYRE) reported deferred revenue of $840K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s deferred revenue changed year-over-year?
- Gyre Therapeutics, Inc.'s deferred revenue increased by 2900.0% year-over-year, from $28K to $840K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), Gyre Therapeutics, Inc.'s deferred revenue has grown at a -62.9% compound annual growth rate (CAGR), from $1.98M to $14K.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.